[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

732.P2.24 Clinical Results - Alternative Donor Transplantation Poster III

Oral and Poster Abstracts
Poster Session
Monday, December 7, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
The Intra-Bone Route of Administration of Cord blood cells extends the Possibility of Transplantation to the Majority of Patients with Malignant Hematopoietic Diseases

Francesco Frassoni, MD1, Marina Podestŕ, BiolSci2*, Simona Pollichieni, Ph.D.3*, Francesca Gualandi, MD4*, GianLuca Ubezio, MD1*, Lucia Garbarino, MD5*, Teresa Lamparelli, MD4*, Riccardo Varaldo, MD6*, Gianmario Sambuceti, MD7*, Myriam Labopin, MD8*, Andrea Bacigalupo, MD4* and Nicoletta Sacchi, Ph.D5*

1Centro Cellule Staminali e Terapia Cellulare, Ospedale San Martino, Genova 16143, Italy
2Centro Cellule Staminali e Terapia Cellulare, Ospedale San Martino, Genova 16132, Italy
3IBMDR Italian Bone Marrow Registry, Genova, Italy
4Department of Hematology II, San Martino's Hospital, Genova, Italy
5IBMDR Italian Bone Marrow Donor Registry, Genova, Italy
6Ospedale San Martino, Centro Cellule Staminali e Terapia Cellulare, Genova, Italy
7Universitŕ Degli Studi di Genova, Genova
8Hopital Saint-Antoine, and EBMT ALWP Office Université Pierre et Marie Curie Paris 6, France, Paris 75571, France

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)

Michael Burke, MD1, Barb Trotz, BA, BSN, MSN1*, Qing Cao, MS2*, Brenda Weigel, MSc, MD1, Ashish Kumar, MBBS, PhD1, Angela Smith, MD, MS1 and Michael Verneris, MD1

1Pediatric Hematology-Oncology-Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
2Biostatistics and Informatics Core-Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors

Elizabeth Shima Rich, MD, PhD1, Andrew Artz, MD, MS1, Theodore Karrison, Ph.D.2*, Lucy A Godley, MD, PhD1, Olatoyosi Odenike, MD1, Loren Joseph, MD3*, Justin Kline, MD1, Vu H. Nguyen, MD1, Guadalupe Martinez, BS1*, Paula del Cerro, RN1*, Lisa Pape, RN1*, Linda Schroeder, RN1*, Scott Allen, BA1*, Sarah Horowitz, BA1*, John Cunningham, MD4*, Richard A. Larson, MD1, Wendy Stock, MD1, Amittha Wickrema, PhD1 and Koen van Besien, MD1

1Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL
2Department of Health Sciences, The University of Chicago Medical Center, Chicago, IL
3Department of Pathology, The University of Chicago Medical Center, Chicago, IL
4Department of Pediatrics, The University of Chicago Medical Center, Chicago, IL

Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma

Bertram Glass, MD, PhD1*, Justin Hasenkamp, MD2*, Anke Goerlitz2*, Peter Dreger3, Joerg Schubert, MD4*, Gerald Wulf, MD5, Maike Nickelsen6*, Lorenz H. Truemper, MD7 and Norbert Schmitz1

1Hematology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany
2Hematology and Oncology, University Medicine Göttingen, Göttingen, Germany
3Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
4Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
5Hematology & Oncology, Medical Center University of Goettingen, Goettingen, Germany
6Haematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany
7Department of Hematology and Oncology, Georg August University, Gottingen, Germany

Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL)

Gregory A. Hale, MD1, Smriti Shrestha, MS, MA2*, Jennifer LeRademacher, PhD2*, Hillard M Lazarus, MD3*, Ginna G. Laport, MD4, Silvia Montoto, MD5* and Parameswaran N Hari, MD2

1All Children's Hosptial - Moffitt Cancer Center, St. Petersburg, FL
2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
3Ireland Cancer Center, University Hospitals Case Medical Center, Cleveland, OH
4Stanford University Medical Center, Stanford, CA
5Queen Mary - University of London, London, United Kingdom

Comparative Analysis of Outcomes of Allogeneic Peripheral Blood Stem Cell Transplantation From Related and Unrelated Donors

Byung Woog Kang, M.D.1*, Shi Nae Kim, M.D.2*, Joon Ho Moon, M.D.1*, Joo-Seop Jung3*, Goon-Jae Cho4*, Deog Yeon Jo5, Yeo-Kyeoung Kim6, Hyeoung Joon Kim, MD7, Hun-Mo Ryoo8, Hyeon Seok Eom, MD, PhD9, Sang Min Lee10*, Young-Don Joo11, Jong Ho Won12, Moo-Rim Park, MD13, Min Kyoung Kim14, Myung Soo Hyun, MD, PhD15* and Sang Kyun Sohn, M.D.1*

1Hematology/Med. Oncology, Kyungpook National University Hospital, Daegu, South Korea
2Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
3Hematology-Oncolology, Busan National University Hospital, Pusan
4Department of Hematology/Oncology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, South Korea
5Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, South Korea
6Hematology-Oncology, Chonnam National University Medical School, Jeollanam-do, South Korea
7Chonnam University Hospital, Kwangju, South Korea
8Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, South Korea
9Department of Internal Medicine, National Cancer Center of Korea, Goyang, South Korea
10Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
11Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
12Soon Chun Hyang University Hospital, Seoul, South Korea
13Dept. of Internal Medicine, Wonkwang Univ. Sch. of Med., Iksan, South Korea
14Internal Medicine, Yeungnam University College of Medicine, Daegu, South Korea
15Department of Internal Medicine, Yeungnam University Medical Center, Daegu, South Korea

Comparative Single Institute Analysis of Cord Blood Transplantation From Unrelated Donors with Unrelated Bone Marrow or Related Peripheral Blood Stem-Cell Transplants in Adult Patients with Acute Myeloid Leukemia / Myelodysplastic Syndrome

Kazuhiro Masuoka1*, Kazuya Ishiwata2*, Masanori Tsuji2*, Shinsuke Takagi2*, Hisashi Yamamoto2*, Yuki Mori2*, Naofumi Matsuno2*, Naoyuki Uchida2, Atsushi Wake2*, Shigeyoshi Makino3*, Akiko Yoneyama4* and Shuichi Taniguchi2*

1Department of Hematology, Mishuku Hospital, Tokyo, Japan
2Department of Hematology, Toranomon Hospital, Tokyo, Japan
3Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan
4Department of Clinical Laboratory, Toranomon Hospital, Tokyo, Japan

Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes

Teresa Field, MD, PhD1, Janelle Perkins, PharmD1*, Mohamed A Kharfan-Dabaja, MD1, Hugo F. Fernandez, MD1, Lia Perez, MD2, J. Leonel Ochoa-Bayona, MD1*, Jeffrey E Lancet, MD3, Rami S. Komrokji, MD4, Melissa Alsina, MD5, Ernesto Ayala, MD6, Alan F List, MD3 and Claudio Anasetti, MD6

1Blood and Marrow Transplantation, H.Lee Moffitt Cancer Center, Tampa, FL
2Blood and Marrow Tranplantation, H. Lee Moffitt Cancer Ctr., Tampa, FL
3Department of Hematologic Malignancies, H. Lee Moffitt Cancer Center, Tampa, FL
4Department of Hematologic Malignancies, H.Lee Moffitt Cancer Center, Tampa, FL
5Blood and Marrow Transplantation, H. Lee Moffitt Cancer Ctr., Tampa, FL
6Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort

Andrew Daly, MD, FRCPC1, Douglas A. Stewart, MD, FRCPC2, Ahsan Chaudhry, MD3*, Nizar J Bahlis, MD, FRCPC3, Christopher Brown, MD, FRCPC2, Peter Duggan, MD, FRCPC3, Michelle Geddes, MD, FRCPC3, Mary Lynn Savoie, MD, FRCPC3, Jan Storek, MD, PhD3*, Maggie Yang4* and James A. Russell, MD, FRCPC2

1Department of Medicine/Hematology, Peter Lougheed Centre, Calgary, AB, Canada
2Department of Medicine/Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada
3Department of Medicine/Hematology, Foothills Medical Centre, Calgary, AB, Canada
4Alberta Blood and Marrow Transplant Program, Calgary, AB, Canada

Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: Similar Efficacy of Non-Myeloablative and Myeloablative Conditioning; Long-Term Evaluation From the University of Minnesota

Brian McClune, DO1, Linda J. Burns, MD2, Todd E. DeFor, MS3*, Arne Slungaard, MD2, Veronika Bachanova4, Claudio Brunstein, MD, PhD2 and Daniel J. Weisdorf2*

1Dept. of Medicine, University of Minnesota, Minneapolis, MN
2University of Minnesota, Minneapolis, MN
3Cancer Center, University Of Minnesota, Minneapolis, MN
4Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Impact of Early Lymphocyte Recovery On Transplant Outcome After Cord Blood Transplantation

Sara K Tedeschi1*, Brian Engelhardt, MD1, Waleed Khalaf1*, Janice Tracy1*, Jennifer Domm1*, Wichai Chinratanalab2*, Adetola A. Kassim, MD, MS1, Stacey Goodman, MD2*, John P. Greer, MD1, Friedrich Schuening, MD1, Madan Jagasia, MD, MS1, Haydar Frangoul, MD1 and Bipin N. Savani, MD2

1Hematology and Stem Cell Transplantation Section, Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
2Hematology and Stem Cell Transplantation Section, Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN

Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML

Nicolaus Kröger, MD1*, Tatjana Zabelina2*, Christine Wolschke3*, Heinrich Lellek3*, Thomas Stübig1*, Maite Lestin1*, Haefaa Alchalby4*, Francis Ayuk5*, Ulrike Bacher6*, Boris Fehse1* and Axel R. Zander2

1Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
2Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
3Institute for Transfusion Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany
4Stem cell Transplantation, University Hospital Hamburg, Hamburg, Germany
5Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
6University Hospital, Hamburg, Germany

Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients

Michael Stadler, MD*, Elke Dammann*, Stefanie Buchholz, MD*, Bernd Hertenstein, MD*, Juergen Krauter, MD*, Matthias Eder, MD* and Arnold Ganser, MD

Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Matched Unrelated Donor Allogeneic Stem Cell Transplantation in High Risk Acute Lymphoblastic Leukemia (ALL) After a Preparative Regimen of Hyperfractionated Total Body Irradiation and High-Dose Etoposide – A Feasibility Study within the German Multicenter Study Group for Adult ALL

Dietrich W. Beelen, MD, PhD1*, Renate Arnold, MD, PhD2, Theis Terwey, MD2*, Nina K. Steckel, MD1*, Nicola Goekbuget, MD3* and Hoelzer Dieter, MD, PhD3*

1Department of Bone Marrow Transplantation, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
2Department of Hematology and Oncology, Charité - University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany
3Department of Internal Medicine II, Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

Mitoxantrone, Not Idarubicin, Significantly Improves the Outcome of Children with Relapsed ALL – Result of the International, Randomised ALLR3 Study

Catriona Parker1*, Rachel Waters2*, Carly Leighton1*, Jeremy Hancock3*, Anthony Moorman4, Mary Morgan5*, Philip Ancliff6*, Nicholas Goulden6*, Rosemary Sutton7*, Tamas Revesz8*, Philip Darbyshire9*, Sharon Love2* and Vaskar Saha1

1School of Cancer, Enabling Sciences and Technology, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
2Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom
3Bristol Genetics Laboratory, Bristol MRD Group, Bristol, United Kingdom
4Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom
5Child Oncology and Haematology Centre, Southampton General Hospital, Southampton, United Kingdom
6Department of Haematology, Great Ormond Street Hospital, London, United Kingdom
7Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia
8Children, Youth and Women's Health Service, Adelaide, Australia
9Department of Haematology, Birmingham Children's Hospital, Birmingham, United Kingdom

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM)

Marcello Rotta, MD1*, Barry E Storer2*, Thoralf Lange, MD3*, Michael Pulsipher, MD4, Judith Shizuru, MD, PhD5, Benedetto Bruno, MD, PhD6*, Peter A. McSweeney, MD7, Edward Agura, MD8, Thomas Chauncey, MD, PhD9*, Frederick R Appelbaum, MD2, William Bensinger, MD2*, Brenda M Sandmaier, MD2, Rainer F Storb2, George E. Georges, MD10 and David G Maloney, MD, PhD2

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Fred Hutchinson Cancer Research Center & U. of Washington, Seattle, WA
3Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany
4University of Utah Medical Center, Salt Lake City, UT
5Stanford University, Stanford, CA
6University of Torino, Torino, Italy
7Rocky Mountain Blood and Marrow Transplant Program, Denver, CO
8Baylor Sammons Cancer Center, Dallas, TX
9VA Puget Sound Health Care System, Seattle, WA
10Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia

Jiri Pavlu1*, Andrea Kew2, Beatrice Taylor-Roberts1*, Holger Auner1*, John Goldman1*, Jane Apperley3 and Richard Szydlo1*

1Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
2Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
3Department of Hematology, Imperial College at Hammersmith Hospital, London, United Kingdom

Outcome of HLA-Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation Depends On the Intensity of the Conditioning Regimen

Francis Ayuk, MD1*, Tatjana Zabelina, MD1*, Ulrike Bacher, MD1*, Christine Wolschke, MD1*, Heinrich Lellek, MD1*, Thomas Eiermann, MD2*, Rudolf Erttmann, MD1*, Nicolaus Kröger, MD1* and Axel R. Zander, MD1

1Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
2Department of Transfusion Medicine, University Medical Center Hamburg, Hamburg, Germany

Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP)

Marcos de Lima, MD1*, John D. McMannis, PhD1, Chitra Hosing, MD1, Partow Kebriaei, MD2, Simon Robinson, Ph.D.1*, Susan Kelly, MD1*, Leandro de Padua Silva, MD1*, Marcelo Fernandez-Vina1*, Alexandre Chiattone, MD1*, Doyle Bosque, RN1*, Gabriela Rondon1, Sergio Giralt, MD1, Laurence Cooper, MD1, Julianne J Chen1*, Simrit Parmar, MD1, Roy Jones, MD1*, Borje Andersson, MD1*, Laura Worth, MD, PhD1, Amin Alousi, MD1*, Ian K. McNiece, PhD3, Krishna V. Komanduri, M.D.3*, Paul J Simmons, MD, PhD4, Richard E Champlin, MD1* and Elizabeth J. Shpall, MD1

1Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3University of Miami, Miami, FL
4Center for Stem Cell Research, Institute of Molecular Medicine, Houston, TX

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN):  Results of the University of Chicago Experience

Vaishalee P. Kenkre, MD1, Sarah Horowitz2*, Richard A. Larson, MD3, Andrew Artz, MD, MS4, Elizabeth Shima Rich, MD, PhD3, Yanming Zhang, M.D., M.S.5*, Michelle M. Le Beau, PhD3, Lucy A Godley, MD, PhD6, Olatoyosi Odenike, MD3, Michael Thirman, MD7, Koen van Besien, MD8 and Wendy Stock, MD9

1Medicine (Hem./Onc.), Univ. of Chicago Medical Center, Chicago, IL
2Medicine - Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
3University of Chicago, Chicago, IL
4University of Chicago Hospital, Chicago, IL
5Dept. of Medicine, The University of Chicago, Chicago, IL
6Univ. of Chicago Med. Ctr., Chicago, IL
7Medicine, University of Chicago, Chicago, IL
8Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL
9Section Hem./Onc., University of Chicago, Chicago, IL

The Beneficial Impact of KIR-Ligand Mismatch and Absence of Donor-KIR2DS3 Gene On Outcome Following Unrelated Donor Stem Cell Transplantation for Myeloid Leukemia

Gongqiang Wu*, Yanmin Zhao*, Xiaoyu Lai*, Yamin Tan*, Yi Luo*, Jimin Shi*, Wanzhuo Xie*, Li Li*, Gaofeng Zheng*, Zhen Cai*, Maofang Lin* and He Huang, MD, PhD

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

The Outcome of Unrelated Hematopoietic Stem Cell Transplants with Total Body Irradiation (800 cGy) and Cyclophosphamide (120 mg/kg) in Adult Patients with Severe Aplastic Anemia

Jong Wook Lee1, Byung Sik Cho1*, Yoo-Jin Kim2, Hee Je Kim1*, Seok Lee1, Chang Ki Min3*, Seok Goo Cho1*, Woo Sung Min1*, Chong Won Park1* and Chun Choo Kim1*

1The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
2Hematology, Internal Medicine, Catholic BMT Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
3The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea

Transplantation Following Myeloablative Cytoreduction Results in Excellent Survival, Long-Term Engraftment, and Donor Chimerism in Children with Chronic Granulomatous Disease Across Donor and Graft Sources

Priti Tewari, MD, Susan Wood, PNP*, Paul L Martin, MD, PhD*, Suhag H Parikh, MD*, Paul Szabolcs, MD*, Kristin M Page, MD*, Timothy Driscoll, MD*, Joanne Kurtzberg, MD and Vinod K. Prasad, MBBS, MD, MRCP

Division of Blood and Marrow Transplantation, Department of Pediatrics, Duke University Medical Center, Durham, NC

Treatment of High Risk Inherited Lysosomal and Peroxisomal Disorders Using Reduced Intensity Hematopoietic Cell Transplantation

Angela Smith, MD, MS, Jakub Tolar, MD, PhD, Teresa J Kivisto, RN, BSN*, Troy Lund, MD, PhD and Paul Orchard, MD

University of Minnesota, Minneapolis, MN

*signifies non-member of ASH